HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors Nov 18, 2022 By sarahjibrin
Sep 5, 2022 By jeromer HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO Congress
Apr 27, 2022 By sarahjibrin HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 18, 2022 By sarahjibrin HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment
Apr 18, 2022 By sarahjibrin Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors
Apr 18, 2022 By sarahjibrin Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization
Apr 4, 2022 By sarahjibrin HiFiBiO Therapeutics Announces Three Presentations at 2022 American Association for Cancer Research (AACR) Annual Meeting
Sep 23, 2021 By sarahjibrin HiFiBiO Therapeutics Contributes to CoVIC-Led Science Publication on SARS-CoV-2 Spike Antibodies Effective Against Variants of Concern
Jun 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy
May 11, 2021 By sarahjibrin HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody
Apr 12, 2021 By sarahjibrin Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody
